Tumor treating fields in malignant pleural mesothelioma: from cytoskeletal collapse to immunophenotypic conversion

Our plain-English summary of Tumor treating fields in malignant pleural mesothelioma: from cytoskeletal collapse to immunophenotypic conversion, by X. Ma, Z. Zuo, Y. Sun, et al (Frontiers in Immunology, 2026).

The study

• Authors: X. Ma, Z. Zuo, Y. Sun, H. An
• Journal: Frontiers in Immunology
• Published: 2026;17:1782708
• Type of article: Review
• Read it: PubMed · Publisher · Free full text

Abstract

The therapeutic efficacy in malignant pleural mesothelioma (MPM) is severely hindered by its dense stromal barrier and immunosuppressive microenvironment. Although Tumor Treating Fields (TTFields) have demonstrated significant survival benefits in clinical trials, their underlying mechanisms extend well beyond simple mitotic arrest. This review delineates a "multidimensional biophysical remodeling" atlas of TTFields in MPM. First, we highlight that TTFields physically disrupt actin-dependent intercellular "tunneling nanotubes, " thereby severing the tumor's communication and metabolic rescue networks. Second, physical stress downregulates the Fanconi Anemia-BRCA pathway, inducing a state of "conditional BRCAness" that specifically sensitizes tumors to DNA-damaging agents. Finally, this cascade triggers immunogenic cell death and orchestrates a chemokine storm, which is hypothesized to facilitate the conversion of the tumor microenvironment from an immune "cold" to a "hot" phenotype. Collectively, by integrating the physical disintegration of subcellular structures with immunological remodeling, TTFields may offer a hypothetical theoretical framework for overcoming therapeutic resistance in MPM.

Copyright © 2026 Ma, Zuo, Sun and An.

In plain English

This article is a review, not an original study. The authors gathered published laboratory, animal and clinical research on Tumor Treating Fields (TTFields), a treatment that applies alternating electric fields to the tumor, in malignant pleural mesothelioma, a cancer the article describes as closely associated with asbestos exposure. They did not say how studies were found or how many were reviewed. Among the work they described, the single-arm phase II STELLAR trial reported a median overall survival of 18.2 months in patients with unresectable mesothelioma given TTFields with standard first-line chemotherapy. Laboratory studies by other researchers reported that TTFields reduced tube-like connections between mesothelioma cells and lowered levels of several DNA-repair proteins. In the laboratory, TTFields combined with cisplatin had a synergistic effect, and combined with pemetrexed a mainly additive one. The authors presented the idea that TTFields turn immune 'cold' tumors 'hot' as a hypothesis. They concluded that their framework gives a theoretical basis for future combinations with immunotherapy or DNA-repair inhibitors. They noted that the evidence on cell connections came mainly from 2D cell cultures and that STELLAR had no randomized control group.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Narrative review proposing a mechanistic framework ("atlas") for how TTFields act in malignant pleural mesothelioma; no original data
• Who was studied: Published preclinical studies (mesothelioma cell lines such as MSTO-211H and H2052, a murine mesothelioma model, models of other cancers) and clinical trials concerning malignant pleural mesothelioma, which the article describes as closely associated with asbestos exposure; no search method or study count reported
• Exposure: Tumor Treating Fields: alternating electric fields at 150 kHz for mesothelioma and low intensity (1 to 3 V/cm), alone or with chemotherapy (cisplatin/carboplatin plus pemetrexed) or immunotherapy. Asbestos itself was not studied.
• Main results:
  • Cited STELLAR single-arm phase II trial: patients with unresectable mesothelioma given TTFields plus standard first-line chemotherapy had a median overall survival of 18.2 months
  • Cited study by Sarkari et al.: TTFields at 1.0 V/cm and 200 kHz inhibited tunneling nanotube formation in biphasic mesothelioma cells (e.g., MSTO-211H) in vitro
  • Cited study by Mumblat et al.: in MSTO-211H and H2052 mesothelioma cells, TTFields reduced levels of the DNA-repair proteins FANCA, FANCD2, FANCJ and BRCA1
  • Cited in vitro work: TTFields with cisplatin was described as synergistic, while TTFields with pemetrexed was mainly additive
  • Cited study by Sarkari et al.: in a murine mesothelioma model, Tenascin C and VEGFA expression were downregulated in tumor regions after TTFields
• The authors' conclusion: The authors concluded that their mechanistic framework provides a theoretical basis for exploring future strategies combining TTFields with immune checkpoint inhibitors or DNA repair inhibitors
• Limitations the authors state:
  • Evidence that TTFields block cell-to-cell communication comes mainly from 2D in vitro cell cultures
  • Research on induced BRCAness has focused on specific cell lines, so it is unclear whether it occurs in all subtypes
  • The main clinical evidence, the STELLAR trial, was single-arm and non-randomized and was compared with historical controls
  • There are no head-to-head or high-level data on TTFields combined with current standard immunotherapy
  • There are no validated predictive biomarkers to select patients who benefit
  • Possible publication bias and selective reporting of positive preclinical findings
  • Much of the biophysical understanding is extrapolated from glioblastoma models
  • TTFields can trigger protective autophagy, which may counteract efficacy

Topics

The National Library of Medicine indexes this study under subjects our site covers: Lung cancer, Mesothelioma.

Medical terms in this study, explained in our Lexicon: Tumor Treating Fields (TTFields), Pleural Mesothelioma, Clinical Trial, Tumor Microenvironment.

Related studies

• Alteration of cytoskeletal molecules in a human T cell line caused by continuous exposure to chrysotile asbestos — M. Maeda, Y. Chen, et al. (2013)
• Treatment with tumor-treating fields (TTFields) suppresses intercellular tunneling nanotube formation in vitro and upregulates immuno-oncologic biomarkers in vivo in malignant mesothelioma — A. Sarkari, S. Korenfeld, et al. (2023)
• Tumor Treating Fields dually activate STING and AIM2 inflammasomes to induce adjuvant immunity in glioblastoma — D. Chen, S.B. Le, et al. (2022)
• The Mechanisms of Action of Tumor Treating Fields — J.C. Moser, E. Salvador, et al. (2022)
• Tumor Treating Fields (TTFields) Hinder Cancer Cell Motility through Regulation of Microtubule and Acting Dynamics — T. Voloshin, R.S. Schneiderman, et al. (2020)
• Prevention and Management of Dermatologic Adverse Events Associated With Tumor Treating Fields in Patients With Glioblastoma — M.E. Lacouture, M.J. Anadkat, et al. (2020)

Browse more research in Frontiers in Immunology, or return to medical research.